BOULDER, Colo., Aug. 1, 2011 /PRNewswire-iReach/ -- WAVi Co. announced today it has entered into a collaboration agreement with SomaLogic, Inc. Under the agreement, WAVi will apply its unique bioinformatics expertise to SomaLogic's proprietary proteomic assays for an undisclosed fee. In addition, the companies agree to work together to plan two clinical research studies in dementia that will combine WAVi's EEG (electroencephalogram)-based biomarkers and SomaLogic's blood-based protein biomarkers.
"This collaboration with SomaLogic validates both our world-class bioinformatics capabilities as well as the potential of WAVi's brain assessment platform – a platform designed as a point of care, rapid screening device providing an objective and accurate measurement to aid in the early detection and diagnosis of cognitive ailments and other neurological disorders," said Stephen K. Onody, President and CEO of WAVi. "Our mission is pre-symptomatic detection leading to early diagnosis enabling timely treatmentof cognitive ailments. Dementia costs the U.S. $183 billion per year and it is estimated that 1 in 8 people will develop Alzheimer's. The WAVi system is designed to assist physicians to ensure patients are treated or referred to specialist care when need exists."
Larry Gold, PhD, SomaLogic Chief Executive Officer added "We are delighted to begin this collaboration with WAVi, and believe that our unique contributions to our joint work will speed the early detection and diagnosis not just of dementia but many different human diseases, offering the possibility for earlier and more effective therapeutic interventions."
About WAVi Co.
WAVi Co. (www.ewavi.com) is a privately held, medical technology company developing the first simple to use, low-cost, EEG brain assessment platform suitable for mass screening. The WAVi device
|SOURCE WAVi Co.|
Copyright©2010 PR Newswire.
All rights reserved